479
Views
3
CrossRef citations to date
0
Altmetric
Author's View

BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system

, , &
Article: e1122159 | Received 12 Nov 2015, Accepted 14 Nov 2015, Published online: 29 Apr 2016

Figures & data

Figure 1. (A) A diagram representing our model of CML and the autologous immune system. Leukemic cells are divided into cycling and quiescent stem cells, progenitors, and mature cells, while there is a single immune cell compartment. Unlabeled arrows indicate transitions of leukemic cells between the compartments. Outgoing arrows indicate cell death, which can occur naturally (N) or as a result of an immune response (I). (B) Four representative fits of our model to patient data. Dots represent patient data, while the thick solid lines are our fits. Dashed lines mark the ends of the immune window. The horizontal dotted lines at y = −3.5 approximate the minimal leukemic concentration that is detectable by quantitative RT-PCR. Dots along this line represent zero measurements.

Figure 1. (A) A diagram representing our model of CML and the autologous immune system. Leukemic cells are divided into cycling and quiescent stem cells, progenitors, and mature cells, while there is a single immune cell compartment. Unlabeled arrows indicate transitions of leukemic cells between the compartments. Outgoing arrows indicate cell death, which can occur naturally (N) or as a result of an immune response (I). (B) Four representative fits of our model to patient data. Dots represent patient data, while the thick solid lines are our fits. Dashed lines mark the ends of the immune window. The horizontal dotted lines at y = −3.5 approximate the minimal leukemic concentration that is detectable by quantitative RT-PCR. Dots along this line represent zero measurements.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.